<DOC>
	<DOCNO>NCT02638493</DOCNO>
	<brief_summary>Male participant take tenofovir-emtrictabine ( TDF/FTC ) provide semen blood sample analyze good understand pharmacology antiretroviral therapy male genital tract .</brief_summary>
	<brief_title>The Compartmental Biology HIV Male Genital Tract</brief_title>
	<detailed_description>8 HIV positive men take TDF/FTC 8 HIV negative men take TDF/FTC pre-exposure prophylaxis provide multiple semen blood sample 48-hour inpatient visit . 8 HIV positive men take TAF ( tenofovir alafenamide ) provide multiple semen blood sample 48-hour inpatient visit . Participants take part study approximately two month . After screen visit , one 2 day overnight visit intensive PK/PD ( pharmacokinetic/pharmacodynamic ) sampling . The investigator study drug concentration intracellular endogenous nucleotide concentration ( dATP dCTP ) seminal plasma ( appropriate ) seminal cell . Samples analyze use novel laboratory method determine seminal plasma seminal cell concentration tenofovir emtricitabine . New technology use well understand compartmental intracellular antiretroviral pharmacology nucleoside/tide reverse transcriptase inhibitor . Pharmacokinetic modeling use estimate primary outcome .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Born male age 18 60 HIV positive take TDF/FTC ( third drug ) treatment ; HIV negative men receive TDF/FTC preexposure prophylaxis ; HIV positive men take tenofovir alafenamide routine treatment must take medication least 3 month adherence medication assess blood plasma HIV RNA le 50 copy per mL . documentation least 80 % adherence ART regimen , clinician selfreport , miss dos 3 day prior inpatient visit . willing able comply schedule visit , treatment plan , laboratory test , trial procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic disease would pose unnecessary risk interfere study result . unwilling unable abstain sexual activity 72 hour prior overnight sample visit unlikely remain current drug regimen study period anemia precludes blood donation unable provide semen specimen current receipt medication may affect endogenous nucleotide concentration , additional HIV nucleoside reverse transcriptase inhibitor , ribavirin , adefovir</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>tenofovir-emtrictabine</keyword>
	<keyword>antiretroviral therapy</keyword>
	<keyword>Prevention</keyword>
	<keyword>tenofovir alafenamide</keyword>
</DOC>